Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from AstraZeneca

AstraZeneca Moves From ADRs To NYSE Listing

The Board of AstraZeneca plc (NASDAQ: AZN) is recommending to shareholders a Harmonized Listing Structure for the company's ordinary shares across the London Stock Exchange (LSE), Nasdaq Stockholm (STO), and the New York Stock Exchange (NYSE).

Benzinga

AstraZeneca will list shares directly in New York, but isn't leaving the UK

Amid concerns it might leave the UK, the pharma giant reaffirmed its commitment to the country, keeping its headquarters, primary listing, and tax base there.

Euronews

Emma Walmsley steps down as CEO of GSK as pharmaceutical industry faces upheaval

The drug and vaccine maker is a £60bn firm – one of the biggest in the UK

The Independent UK

From analysis to the latest developments in health,
read the most diverse news in one place.

GSK Switches CEO As Trump Tariffs Test Pharma

British pharmaceutical giant GSK on Monday said longtime chief executive Emma Walmsley will be replaced by its chief commercial officer in January, as the company navigates US tariffs on the sector.

International Business Times

AstraZeneca to upgrade US listing in ‘knock-back for London’

UK’s biggest drugmaker will put its US shares on a par with its London-based stock but says HQ will stay in Cambridge

The Guardian - UK

AstraZeneca to overhaul US listing but remain on London market and keep UK HQ

The Cambridge-based firm is set to directly list its ordinary shares on the New York Stock Exchange amid an increased focus on the US.

Evening Standard

Your AstraZeneca Medicine Could Be Cheaper As Much As 70%

AstraZeneca Plc (NASDAQ: AZN) launched AstraZeneca Direct, an online platform designed to create a simple, convenient way for eligible patients to access their prescribed medications at a transparent cash price with home delivery.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

NHS facing ‘critical threat’ after Trump pressure to hike drug prices

NEWS ANALYSIS: Drug prices in the UK could rise amid 100 per cent tariffs on branded medicines and pressure from US President Donald Trump to stop ‘global freeloading’, Alicja Hagopian reports

The Independent UK

Brighter US outlook fires up European stocks

The FTSE 100 index closed up 70.85 points, or 0.8%, at 9,284.83.

Evening Standard

UK fuel retailers accused of ‘ripping off’ motorists at the pumps; markets shrug off latest Trump tariffs – as it happened

Rolling coverage of the latest economic and financial news

The Guardian - UK

UK is ‘worst country in Europe’ for drug prices, says Mounjaro maker

Eli Lilly CEO says Britain’s strict regime means it could miss out on new drugs being rolled out unless it pays more

The Guardian - UK

European Advisory Panel Recommends Two AstraZeneca Drugs For Approval

AstraZeneca Plc (NASDAQ:AZN) and Amgen Inc.'s (NASDAQ:AMGN) Tezspire (tezepelumab) has been recommended for approval in the European Union (EU) for adult patients with chronic rhinosinusitis with nasal polyps (CRSwNP).

Benzinga

AstraZeneca's Fasenra Falls Short In Smoker's Lung Trial

AstraZeneca Plc (NASDAQ:AZN) released on Wednesday topline data from RESOLUTE Phase 3 trial of Fasenra (benralizumab).

Benzinga

UK set on resolving standoff with big pharma, science minister says

Patrick Vallance says relations must improve and NHS has to reverse decline in drugs investment

The Guardian - UK

Get all your
news in one place.

100’s of premium titles.
One news app.

Evening Standard

UK ‘difficult’ operating environment says Merck boss after £1bn London site axed

Last week, Merck’s business in the UK and Europe, MSD, said it will move its life sciences operation to the US, impacting around 125 British jobs.

The Guardian - UK

Big pharma firms have paused nearly £2bn in UK investments this year

Government’s plans in disarray before Trump talks as MSD, Eli Lilly and AstraZeneca moves prompt job fears

The Guardian - UK

The Guardian view on Merck’s exit: Britain’s biopharma strategy stalls in the face of China’s rise

Editorial: The industry’s retreat from the UK reflects a deeper shift about how Beijing is rewriting the rules of innovation

Benzinga

AstraZeneca Puts Cambridge Expansion On Ice Adding Pressure On Starmer Ahead Of Trump Visit

The U.K.-based AstraZeneca Plc (NASDAQ:AZN) paused a planned 200 million pounds ($271.26 million) investment in its Cambridge research site.

Get all your
news in one place.

100’s of premium titles.
One news app.

Evening Standard

AstraZeneca pauses £200m expansion in Cambridge

It comes after the pharmaceutical firm abandoned plans to invest £450 million in a vaccine plant in Merseyside earlier this year.

The Independent UK

Britain’s biggest company AstraZeneca pauses £200m investment into Cambridge site

The investment had been set to create 1,000 jobs

The Guardian - UK

AstraZeneca pauses £200m investment in Cambridge research site

Decision means none of drugmaker’s much-trumpeted £650m UK investment package is currently proceeding

Evening Standard

Merck’s move to axe £1bn UK expansion was ‘commercial decision’, says minister

The Conservatives said Merck’s decision should send alarm bells ringing across Government.

Benzinga

FDA Expands Approval For AstraZeneca's Drug For Pediatric Patients With Rare Type Of Cancer

On Wednesday, the U.S. Food and Drug Administration (FDA) approved AstraZeneca Plc’s (NASDAQ:AZN) Koselugo (selumetinib) granules and capsules for pediatric patients 1 year of age and older with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN), benign, nerve sheath tumors.

Benzinga

AstraZeneca Lung Cancer Combo Extends Patient Survival By Years In Key Study

On Sunday, AstraZeneca Plc (AZN) released results from the final overall survival (OS) analysis of the FLAURA2 Phase 3 trial in previously untreated patients with locally advanced (Stage IIIB-IIIC) or metastatic (Stage IV) non-small cell lung cancer (NSCLC) whose tumors have EGFR exon 19 deletion or exon 21 L858R mutations.

Benzinga

AstraZeneca, Corning And More On CNBC's 'Final Trades'

On CNBC's “Halftime Report Final Trades,” Jim Lebenthal, partner at Cerity Partners, named AstraZeneca PLC (NASDAQ:AZN) as his final trade.

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

the London Stock Exchange

the New York Stock Exchange

141 stories

Sprint

136 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.